Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA

Walleye Capital LLC purchased a new stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 386,183 shares of the company’s stock, valued at approximately $14,393,000. Walleye Capital LLC owned 0.44% of IDEAYA Biosciences as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Janus Henderson Group PLC lifted its stake in shares of IDEAYA Biosciences by 1.1% in the 1st quarter. Janus Henderson Group PLC now owns 7,265,253 shares of the company’s stock worth $242,023,000 after purchasing an additional 78,797 shares during the period. Vanguard Group Inc. grew its position in IDEAYA Biosciences by 2.0% during the fourth quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock valued at $173,518,000 after buying an additional 97,116 shares during the period. State Street Corp grew its position in IDEAYA Biosciences by 27.6% during the fourth quarter. State Street Corp now owns 4,134,641 shares of the company’s stock valued at $142,935,000 after buying an additional 893,707 shares during the period. Baker BROS. Advisors LP increased its holdings in IDEAYA Biosciences by 10.5% during the fourth quarter. Baker BROS. Advisors LP now owns 3,618,826 shares of the company’s stock valued at $125,103,000 after buying an additional 343,382 shares during the last quarter. Finally, Fiera Capital Corp increased its holdings in IDEAYA Biosciences by 32.6% during the fourth quarter. Fiera Capital Corp now owns 2,437,262 shares of the company’s stock valued at $84,256,000 after buying an additional 599,295 shares during the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

Analyst Ratings Changes

IDYA has been the topic of several recent research reports. Truist Financial decreased their price target on shares of IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Wall Street Zen downgraded shares of IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Mizuho reduced their price objective on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Wedbush raised their target price on IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Finally, Royal Bank Of Canada decreased their target price on IDEAYA Biosciences from $53.00 to $48.00 and set an “outperform” rating on the stock in a report on Tuesday, July 7th. Fourteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $50.12.

IDEAYA Biosciences Trading Down 1.0%

Shares of NASDAQ:IDYA opened at $36.30 on Friday. The stock has a 50 day moving average of $35.19 and a 200 day moving average of $32.71. The company has a market cap of $3.19 billion, a PE ratio of -18.71 and a beta of -0.10. IDEAYA Biosciences, Inc. has a 12-month low of $23.23 and a 12-month high of $40.58.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The firm had revenue of $8.86 million for the quarter, compared to the consensus estimate of $8.02 million. During the same quarter in the previous year, the business posted ($0.88) EPS. IDEAYA Biosciences’s revenue was up 8800.0% on a year-over-year basis. Equities research analysts predict that IDEAYA Biosciences, Inc. will post -4.38 earnings per share for the current fiscal year.

Insider Activity

In other news, CAO Briseno Andres Ruiz sold 9,550 shares of the stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $40.01, for a total value of $382,095.50. Following the completion of the sale, the chief accounting officer directly owned 26,466 shares of the company’s stock, valued at $1,058,904.66. This represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.70% of the stock is currently owned by company insiders.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.